Ultragenyx
RARE
$43.85
Share price
-0.97%
Change (1 day)
4.78%
Change (1 year)
Categories
Earnings for Ultragenyx (RARE)
Earnings in 2023 (TTM): -$0.55 B
According to Ultragenyx's latest financial reports the company's current earnings (TTM) are -$0.55 B. In 2022 the company made an earning of -$0.66 B a decrease over its 2021 earnings that were of -$0.43 B.The earnings displayed on this page is the company's Pretax Income.
Earnings history for Ultragenyx from 2013 to 2023
Annual earnings
| Year | Earnings | Change |
|---|---|---|
| 2023 (TTM) | -$0.55 B | -17.65% |
| 2022 | -$0.66 B | 55.52% |
| 2021 | -$0.43 B | 178.53% |
| 2020 | -$0.16 B | -59.64% |
| 2019 | -$0.38 B | 1.46% |
| 2018 | -$0.38 B | 12.9% |
| 2017 | -$0.33 B | 32.63% |
| 2016 | -$0.25 B | 67.87% |
| 2015 | -$0.15 B | 160.2% |
| 2014 | -$56.78 M | 66.64% |
| 2013 | -$34.08 M |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Lexicon Pharmaceuticals
LXRX | -$0.18 B | -67.35% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | -$0.16 B | -72.30% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | -$0.16 B | -72.33% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | $0.18 B | -134.76% | 🇺🇸 USA |